MX2012013023A - Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. - Google Patents

Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.

Info

Publication number
MX2012013023A
MX2012013023A MX2012013023A MX2012013023A MX2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A
Authority
MX
Mexico
Prior art keywords
venlafaxine
extended release
alcohol
dosage forms
release dosage
Prior art date
Application number
MX2012013023A
Other languages
English (en)
Inventor
Ehab Hamed
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of MX2012013023A publication Critical patent/MX2012013023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Esta descripción se relaciona con una forma de dosificación oral de liberación prolongada que comprende una matriz que contiene un modificador de la viscosidad (pero ningún lípido) y gránulos recubiertos que contienen venlafaxina o una sal farmacéuticamente aceptable o solvato de lo mismo. La forma farmacéutica de dosificación tiene resistencia al alcohol y también puede tener resistencia a la trituración.
MX2012013023A 2010-05-11 2011-05-09 Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. MX2012013023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33352710P 2010-05-11 2010-05-11
PCT/US2011/035768 WO2011143119A1 (en) 2010-05-11 2011-05-09 Alcohol-resistant extended release dosage forms comprising venlafaxine

Publications (1)

Publication Number Publication Date
MX2012013023A true MX2012013023A (es) 2012-12-17

Family

ID=44461928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013023A MX2012013023A (es) 2010-05-11 2011-05-09 Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.

Country Status (6)

Country Link
US (1) US20130171256A1 (es)
EP (1) EP2579857A1 (es)
JP (1) JP2013526522A (es)
CA (1) CA2798701A1 (es)
MX (1) MX2012013023A (es)
WO (1) WO2011143119A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015284078B2 (en) 2014-07-03 2020-01-30 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
CA3112030A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
IL149055A0 (en) * 2002-04-09 2002-11-10 Karma Pharm Ltd Extended release composition comprising as active compound venlafaxine hydrochloride
IN2003MU00504A (es) * 2003-06-05 2005-05-13 Alembic Ltd
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
WO2007112574A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Extended release composition of venlafaxine
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
MX336861B (es) * 2007-09-13 2016-02-04 Cima Labs Inc Formulacion de farmaco resistente al abuso.

Also Published As

Publication number Publication date
WO2011143119A1 (en) 2011-11-17
US20130171256A1 (en) 2013-07-04
JP2013526522A (ja) 2013-06-24
EP2579857A1 (en) 2013-04-17
CA2798701A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
MX347753B (es) Formulaciones resistentes al abuso.
MX2012013021A (es) Formulaciones resistentes a alcohol.
NZ600640A (en) Abuse-resistant formulations
IL199554B (en) Cyclopamine-like compounds and their use for the preparation of anti-proliferative drugs
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
MX345777B (es) Formulaciones de tabletas bicapa.
EP2591773A4 (en) TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION
ZA201101477B (en) Co-crystals and pharmaceutical formulations comprising the same
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
DK2442790T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyolkomplekser
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
IL218008A (en) Dexbinol or its salt for non-melanoma cancer suppression, its use in the preparation of non-melanoma cancer suppressant, and a pharmacological preparation containing the said
EP2542082B8 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
UY31887A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la cardioversión
PL2168584T3 (pl) Kompozycja farmaceutyczna zawierająca kombinację triazolobenzodiazepiny i selektywnego inhibitora wychwytu zwrotnego serotoniny
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
SI1952805T1 (sl) Tableta, ki vsebuje hidrogenirane fosfolipide
WO2012111961A3 (ko) 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제